A K Ng

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue
    A K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Ann Oncol 16:1949-55. 2005
  2. ncbi A randomized phase II trial of amifostine for head and neck irradiation in lymphoma
    Andrea K Ng
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 31:20-4. 2004
  3. ncbi Secondary malignancies across the age spectrum
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 20:67-78. 2010
  4. ncbi Review of the cardiac long-term effects of therapy for Hodgkin lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 154:23-31. 2011
  5. ncbi Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease
    A K Ng
    Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    Ann Oncol 15:270-5. 2004
  6. ncbi Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians
    A K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 15:261-9. 2004
  7. ncbi Radiation therapy and breast cancer risk
    Andrea K Ng
    Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:1121-8. 2009
  8. ncbi Diffuse large B-cell lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    Semin Radiat Oncol 17:169-75. 2007
  9. ncbi Health practice in long-term survivors of Hodgkin's lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 71:468-76. 2008
  10. ncbi Second primary cancers: an overview
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, ASB1 L2, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 22:271-89, vii. 2008

Detail Information

Publications44

  1. ncbi A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue
    A K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Ann Oncol 16:1949-55. 2005
    ..To compare the level of fatigue in survivors of Hodgkin's disease and their siblings, and to explore factors associated with increased fatigue...
  2. ncbi A randomized phase II trial of amifostine for head and neck irradiation in lymphoma
    Andrea K Ng
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 31:20-4. 2004
    ..Importantly, fine-tuning the treatment and management approaches to minimize morbidity while maximizing the survival and quality of life of patients are crucial next steps...
  3. ncbi Secondary malignancies across the age spectrum
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 20:67-78. 2010
    ..Moreover, an understanding of the variations in second cancer risk according to age at treatment is important in customizing patient follow-up...
  4. ncbi Review of the cardiac long-term effects of therapy for Hodgkin lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 154:23-31. 2011
    ..Screening for and aggressive management of traditional cardiac risk factors are also important strategies in reducing risks of cardiac disease in long-term Hodgkin lymphoma survivors...
  5. ncbi Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease
    A K Ng
    Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    Ann Oncol 15:270-5. 2004
    ....
  6. ncbi Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians
    A K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 15:261-9. 2004
    ..The aim of this study was to explore variation in practice patterns and identify factors associated with physicians' treatment decisions for early-stage Hodgkin's disease...
  7. ncbi Radiation therapy and breast cancer risk
    Andrea K Ng
    Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:1121-8. 2009
    ..Increased knowledge of radiation-related breast cancer and modifying influences plays an important role in guiding the initial treatment approach for young women and optimizing long-term follow-up care...
  8. ncbi Diffuse large B-cell lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    Semin Radiat Oncol 17:169-75. 2007
    ..In patients with localized DLBCL, available randomized trials suggest that radiation therapy improves local control and disease-free survival and that the addition of radiation therapy cannot replace inadequate chemotherapy...
  9. ncbi Health practice in long-term survivors of Hodgkin's lymphoma
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 71:468-76. 2008
    ..To compare the health practice of Hodgkin's lymphoma (HL) survivors and their siblings, and to assess the impact of socioeconomic status and disease history on health practice of HL survivors...
  10. ncbi Second primary cancers: an overview
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, ASB1 L2, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 22:271-89, vii. 2008
    ..The focus of this article is treatment-associated malignancies in survivors of selected adult cancers...
  11. ncbi A prospective study of pulmonary function in Hodgkin's lymphoma patients
    A K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02114, USA
    Ann Oncol 19:1754-8. 2008
    ..To prospectively study changes in lung function in Hodgkin's lymphoma (HL) patients and to explore predictors for these changes over time...
  12. ncbi Subsequent malignant neoplasms in cancer survivors
    Andrea K Ng
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer J 14:429-34. 2008
    ....
  13. ncbi Late effects of Hodgkin's disease and its treatment
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer J 15:164-8. 2009
    ..As Hodgkin's lymphoma therapy evolve over time, continued documentation of late effects associated with newer treatment will be important for the follow-up of patients treated in the modern era...
  14. ncbi Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
    D J Sher
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA, USA
    Ann Oncol 20:1848-53. 2009
    ....
  15. ncbi Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease
    A K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA
    Ann Oncol 17:1693-7. 2006
    ....
  16. ncbi Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis
    P Das
    Department of Radiation Oncology, U T M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Ann Oncol 17:785-93. 2006
    ..We derived model parameters from published studies and the Surveillance, Epidemiology and End Results (SEER) Program, and assumed that stage-shift produces a survival benefit...
  17. ncbi Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease
    A K Ng
    Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 50:979-89. 2001
    ..CONCLUSIONS: In considering the various alternative management strategies in early-stage Hodgkin's disease, even very small gains in effectiveness were enough to justify the additional costs of more expensive treatment options...
  18. ncbi Late complications of therapy of Hodgkin's disease: prevention and management
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, 75 Francis Street, ASB1-L2, Boston, MA 02115, USA
    Curr Hematol Rep 3:27-33. 2004
    ....
  19. ncbi Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease
    K H Backstrand
    Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:736-41. 2001
    ..The FFTF is especially favorable among stage I patients...
  20. ncbi Clinical course of thoracic cancers in Hodgkin's disease survivors
    P Das
    Department of Radiation Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:793-7. 2005
    ..Hodgkin's disease survivors have a high risk of subsequently developing thoracic cancers. Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease...
  21. ncbi Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 61:175-84. 2005
    ..CONCLUSIONS: Although a positive mid- or postchemotherapy gallium scan was an adverse prognostic factor for OS, FFTF, and PFS, continued treatment with conventional-dose therapy may be adequate in selected patients with positive scans...
  22. ncbi A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation
    Neesha A Rodrigues
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 75:1079-83. 2009
    ..To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)...
  23. ncbi Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome
    J D Schoenfeld
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Oncol 23:1813-8. 2012
    ..Hodgkin lymphoma (HL) survivors have an increased risk of secondary malignancies. We analyzed outcomes in patients with lung cancers following HL treatment...
  24. ncbi Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma
    S K Luthy
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 19:2043-7. 2008
    ..The purpose of this study was to analyze response to palliative low-dose involved-field radiotherapy (LD-IF-RT) (two 2-Gy fractions), explore factors predicting for response, and determine the time course to subsequent treatment...
  25. ncbi Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma
    H K Tsai
    Harvard Radiation Oncology Program, 75 Francis Street, Boston, MA 02115, USA
    Ann Oncol 18:672-8. 2007
    ..Few large studies exist on the outcome of patients treated for stage I/II mucosa-associated lymphoid tissue (MALT) lymphoma...
  26. ncbi Significance of epitrochlear lymph node involvement in Hodgkin disease
    B K Chang
    Department of Radiation Oncology, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 91:1213-8. 2001
    ..If appropriately treated, the prognosis of patients with this unique presentation appears to be similar to that of other HD patients...
  27. ncbi Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors
    Aileen B Chen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 27:5383-9. 2009
    ..We evaluated the cost effectiveness of lipid screening in survivors of HL and compared different screening intervals...
  28. ncbi Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors
    Andrea K Ng
    Department of Radiation Oncology and the Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Blood 100:1989-96. 2002
    ..Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy...
  29. ncbi Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study
    N Khimani
    Department of Radiation Oncology, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston
    Ann Oncol 24:226-30. 2013
    ....
  30. ncbi Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy
    N B Khimani
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:979-84. 2011
    ....
  31. ncbi Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy
    Karen E Hoffman
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 183:1798-802. 2010
    ..In this study we evaluated the influence of health status and life expectancy on prostate specific antigen screening in older men in the United States before the 2008 United States Preventive Services Task Force guidelines...
  32. ncbi Late complications after treatment for Hodgkin lymphoma
    Andrea K Ng
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Hematol Malig Rep 3:119-25. 2008
    ..Continued long-term follow-up of patients treated with modern therapy and documentation of late effects associated with newer treatment will be essential...
  33. ncbi Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease
    Beverly A Guadagnolo
    Joint Center for Radiation Therapy Harvard Radiation Oncology Program, Harvard School of Public Health, Harvard University, Boston, MA 02215, USA
    J Clin Oncol 24:4116-22. 2006
    ..To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD)...
  34. ncbi Controversies in early-stage Hodgkin's disease
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 16:588-95, 598; discussion 600, 605, 609-18. 2002
    ..Along with the evaluation of modified treatments, long-term follow-up efforts should continue in patients who are cured in order to confirm the long-term safety of such therapies...
  35. ncbi Psychological distress in long-term survivors of adult-onset cancer: results from a national survey
    Karen E Hoffman
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Arch Intern Med 169:1274-81. 2009
    ..As advances in cancer screening and treatment increase the number of long-term cancer survivors, it is important to understand the long-term psychological sequelae of the cancer experience...
  36. ncbi Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
    Andrea K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 20:2101-8. 2002
    ..The excess mortality noted beyond two decades underscores the importance of long-term follow-up care in patients treated for Hodgkin's disease...
  37. ncbi Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up
    Ronald C Chen
    Department of Radiation Oncology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 28:136-41. 2010
    ..CONCLUSION RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease...
  38. ncbi Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas
    Neil E Martin
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 50:1765-72. 2009
    ..Overall response rates of more than 80% have been consistently reported with local control maintained for 2 years. In this review, we outline the clinical experience with this approach in NHL of various histologies...
  39. ncbi Radiation therapy for orbital lymphoma
    Ping Zhou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 63:866-71. 2005
    ..To describe radiation techniques and evaluate outcomes for orbital lymphoma...
  40. ncbi Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative
    David E Morris
    Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
    Int J Radiat Oncol Biol Phys 62:3-19. 2005
    ....
  41. ncbi Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma
    Stacie Hitchcock
    Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 52:1058-66. 2002
    ..CONCLUSION: Modest doses of RT provide excellent local control in patients with MALT/MZ NHL. The poor PFS in advanced-stage patients suggests the need to develop alternative systemic treatment strategies for this disease...
  42. ncbi Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations
    Lois B Travis
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 98:15-25. 2006
    ..These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer...
  43. ncbi FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Leuk Lymphoma 45:85-92. 2004
    ..However, more patients have persistently positive PET at the end of chemotherapy compared with gallium (P = 0.04), although only half of these patients have relapsed...
  44. ncbi Role of radiation therapy in localized aggressive lymphoma
    Andrea K Ng
    J Clin Oncol 25:757-9. 2007